硼替佐米
地塞米松
医学
美罗华
内科学
肿瘤科
多发性骨髓瘤
淋巴瘤
作者
Sofiane Salhi,David Ribes,Magali Colombat,Françoise Fortenfant,Stanislas Faguer
标识
DOI:10.1016/j.kint.2021.04.011
摘要
Although B-cell depletion with rituximab has shown promising results in patients with phospholipase-A2 receptor membranous nephropathy (PLA2R+ MN),1 some patients develop refractory MN owing to incomplete B-cell depletion or anti-PLA2R antibody production by plasma cells.2 The best therapeutic option (obinutuzumab3 or belimumab4) in these patients remains elusive. This led us to consider whether plasma cell–directed therapy may be used as salvage therapy in rituximab-resistant PLA2R+ MN.
科研通智能强力驱动
Strongly Powered by AbleSci AI